Fenofibrate May Reduce CVD in Patients With DM, Dyslipidemia

Share this content:
Fenofibrate May Reduce CVD in Patients With DM, Dyslipidemia
Fenofibrate May Reduce CVD in Patients With DM, Dyslipidemia

WEDNESDAY, Jan. 4, 2017 (HealthDay News) -- Fenofibrate therapy may reduce cardiovascular disease (CVD) in statin-treated patients with diabetes and dyslipidemia, according to a study published online Dec. 28 in JAMA Cardiology.

Marshal B. Elam, M.D., Ph.D., from the Memphis Veterans Affairs Medical Center and University of Tennessee Health Sciences Center, and colleagues examined whether fenofibrate reduces CVD risk in statin-treated patients with type 2 diabetes. A total of 4,644 Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Study participants were followed for an additional five years, for a total of 9.7 years.

The researchers found that following completion of ACCORD, only 4.3 percent of study participants continued fenofibrate treatment. Among participants originally randomized to fenofibrate or placebo, high-density lipoprotein and triglyceride values rapidly equalized. During 9.7 years of follow-up, the hazard ratio for the primary study outcome (composite of fatal and nonfatal myocardial infarction and stroke) among participants originally randomized to fenofibrate versus placebo (hazard ratio, 0.93; 95 percent confidence interval, 0.83 to 1.05; P = 0.25) was comparable with that originally seen in ACCORD (hazard ratio, 0.92; 95 percent confidence interval, 0.79 to 1.08; P = 0.32). For participants with dyslipidemia, fenofibrate therapy effectively reduced CVD (hazard ratio, 0.73; 95 percent confidence interval, 0.56 to 0.95).

"The continued observation of heterogeneity of treatment response by baseline lipids suggests that fenofibrate therapy may reduce CVD in patients with diabetes with hypertriglyceridemia and low high-density lipoprotein cholesterol," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry; several pharmaceutical companies provided study medications, equipment, and supplies during ACCORD.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease


Sign up for myCME e-newsletters


More in Home

Adding HIPEC to Cytoreductive Surgery Beneficial in Ovarian CA

Adding HIPEC to Cytoreductive Surgery Beneficial in Ovarian ...

Longer survival with hyperthermic intraperitoneal chemotherapy in stage III epithelial ovarian cancer

Chaplains Effective in Facilitating Advance Care Planning

Chaplains Effective in Facilitating Advance Care Planning

80 percent of patients who met chaplains in medical practice completed or provided advance directive

Alzheimer's Disease Variants Linked to Brain Amyloidosis

Alzheimer's Disease Variants Linked to Brain Amyloidosis

Significant correlations found for adenosine triphosphate-binding cassette subfamily A member

is free, fast, and customized just for you!

Already a member?

Sign In Now »